In vitro, ECJL inhibited xanthine oxidase activity by 41.3 ± 5.5% (dose-dependent) and in vivo, at the doses of 100 and 300 mg/kg, inhibited hepatic xanthine oxidase activity, highly attenuating hyperuricemia. This evidence concerns the gene XDH and hyperuricemia.